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Background: Neurokinins (NKs) participate in asthmatic airway inflammation, but the effects of NKs on airway
smooth muscle cells (ASMCs) and those of corticosteroids on NKs are unknown.
Methods: To investigate the effect of budesonide on substance P (NK-1) receptor (NK-1R) expression in the lung
and ASMCs, 45 Wistar rats were randomly divided into three groups: control, asthmatic, and budesonide treatment.
Aerosolized ovalbumin was used to generate the asthmatic rat model, and budesonide was administered after
ovalbumin inhalation. On day 21, bronchial responsiveness tests, bronchoalveolar lavage, and cell counting were
conducted. NK-1R protein expression in the lung was investigated by immunohistochemistry and image analysis.
Primary rat ASMC cultures were established, and purified ASMCs of the fourth passage were collected for mRNA
and protein studies via real-time RT-PCR, immunocytochemistry, and image analysis.
Results: NK-1R mRNA and protein expression in the budesonide treatment group rat’s lung and ASMCs were less
than that in the asthmatic group but greater than that in the control group.
Conclusions: NK-1R is involved in the pathogenesis of asthma and that budesonide may downregulate the
expression of NK-1R in the ASMCs and airways of asthmatic rats, which may alleviate neurogenic airway
inflammation.Background
Asthma is a chronic inflammatory disease characterized
by airway hyper-responsiveness that involves many in-
flammatory cells and mediators [1]. Neurokinins (NKs)
are peptides synthesized by neural tissues that have been
implicated as the mediators of neurogenic inflammation
in asthma. NKs have potent effects on airway smooth
muscle tone, airway secretion, bronchial circulation, and
inflammatory and immune cells via the activation of
the neurokinin-1 (NK-1R) and neurokinin-2 receptors
(NK-2R); as such, they have been proposed to play an
important role in human respiratory conditions such as
bronchial asthma and chronic obstructive diseases [2].
For example, Pattersson et al demonstrated that tachyki-
nin levels were increased in induced sputum from
patients with asthma, cough, and acid reflux [3]. In
addition, Bai et al also demonstrated that tachykinin,* Correspondence: lmpediatrician@sina.com
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reproduction in any medium, provided the orNK-1R, and NK-2R mRNA expression is elevated within
the airways of asthma patients [4]. Inhaled corticosteroid
treatment is the cornerstone of pharmacotherapy for
persistent asthma [5], and airway smooth muscle cells
(ASMCs) are important in the pathogenesis of this disease;
NK-1R and NK-2R expression in human and rat ASMC
lung tissue has been confirmed by immunohistochemistry
[6,7]. However, the relationship between inhaled corticos-
teroids and NK-1R expression is unknown, and thus, in our
study, we investigated NK-1R expression in asthmatic rat
ASMCs to determine the effect of budesonide treatment
on neuropeptide receptor expression.
Methods
Asthmatic rat model
Forty-five healthy female Wistar rats weighing 150–160 g
were purchased from the experimental animal center of
China Medical University and divided randomly into three
groups: control, asthmatic, and budesonide treatment. All
experimental protocols involving animals were approved byl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Airway responsiveness to MCh. To test the airway responsiveness of asthmatic rats in vivo, we measured respiratory parameters
induced by MCh. Airway responsiveness of rats in the asthmatic group increased in comparison to the control group after induction by MCh.
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and complied with the guidelines of the China Council on
Animal Care. The modified ovalbumin (OVA) (Sigma-
Aldrich, Beijing, China) inhalation method was used to
generate the asthmatic rat model as described in detail
elsewhere [8]. Briefly, the protocol consisted of a subcuta-
neous injection of 1 mg of OVA and 200 mg/mL aluminum
hydroxide (Sigma-Aldrich, Beijing, China) in 1 mL of PBS
and an intraperitoneal injection of 1 mL of heat-killed
Bordetella pertussis (6 × 109/mL, Beijing, China) on day 0
and day 7. Rats in the control group were treated with 1
mL of PBS containing only 200 mg/mL aluminum hydro-
xide. Two weeks later, the rats were placed in a transparent
glass chamber (approximately 20 cm × 20 cm × 20 cm in
volume) connected to an ultrasonic nebulizer (model 100,
Yadu, Shanghai, China) and subjected to repeated bronchial
allergen challenge via OVA (2%) inhalation for 20 min/day
for 6 days. Rats in the control group were challenged with
PBS. After OVA inhalation, rats in the budesonide trea-
tment group were given 1 mg of budesonide via inhalationTable 1 Inflammation cells in different group rat’s BALF (Mea
Group Total Eosinocyto
Asthmatic group 610±32* 461±31*
Budesonide treatment group 372±13#▴ 147±23#▴
normal group 172±21 21±7.5
*P<0.05, compare with normal group;#P<0.05, compare with asthmatic group;▴P>0.0by INQUA NEB plus (PARI) over the course of 5 minutes
for 6 days.
Bronchial responsiveness to methacholine
To investigate OVA-induced effects on airway res-
ponsiveness, we measured changes in respiratory para-
meters in response to methacholine (MCh). After the
rats were challenged, they were anesthetized with
pentobarbital (30 mg/kg, i.p.), and the trachea was
cannulated with a 14-gauge tube. The rats were quasi-
sinusoidally ventilated with a computer-controlled small-
animal ventilator (flexiVent; SCIREQ, Montreal, Quebec,
Canada) with a tidal volume of 8 mL/kg, set automatically
depending on body weight at 90 breaths/min and positive
end-expiratory pressure of 3.0 cmH2O. Airway resistance
was measured by the forced oscillation technique. Five
doses of MCh (Sigma-Aldrich, Beijing, China) solution
(10–160 μg/mL) in 0.5 mL of PBS were given intermittently
via jugular vein injection, each 1 min apart. After each





5, compare with normal group.
Figure 2 Immunohistochemical analysis of NK-1R protein expression in the lung from different groups. A: Representative control group;
B: Representative asthmatic group; C: Representative budesonide treatment group.
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testing baseline airway resistance and Re, which represents
changes in airway responsiveness. When Re reached or
exceeded the baseline Re 2 times stop to push MCh.
Bronchoalveolar lavage (BAL) and cell counting
After the lung responsiveness measurements, the rats
were disconnected from the ventilator and sacrificed via
pentobarbital overdose. A catheter was then inserted
into the trachea, and BAL was performed. The cell sus-
pension was concentrated by centrifugation (1000 rpm,
10 min at 4°C), and the cell pellet was resuspended in 1
mL of saline. To perform the differential leukocyte cell
count, 0.1 mL of the cell suspension was transferred to a
glass slide and stained with Wright-Giemsa stain. A
microscope was then used to examine 400 nucleated cells.
Immunohistochemistry and image analysis
NK-1R protein expression in the lung was detected by
immunohistochemistry. Right middle lobes of the lungs
were harvested 24 h after the final OVA challenge and
fixed in 4% paraformaldehyde, then imbedded in paraf-
fin. Lung sections of 5 μm were cut and blocked with
peroxide and non-immune animal serum and incubated
sequentially with primary antibody, biotin-labeled sec-
ondary antibody, and streptomycin anti-biotin peroxi-
dase. Finally, the sections were stained with DAB,
counterstained with hematoxylin, dehydrated, cleared in
xylene, and fixed. Negative staining controls were gene-
rated by replacing the primary antibody with PBS. The
mean density values of NK-1R protein, indicated by
brown staining, were calculated in three selected fields
under high magnification (×400) via image analysis.Table 2 NK-1R protein expression in the lung from the
different groups
Group Mean ± SE N
normal control group 1.0347±0.2503# 15
asthmatic group 1.1687±0.1356* 15
budesonide treatment group 1.0820±0.1146*# 15
*P < 0.05, compared with normal group; #P < 0.05, compared with asthmatic
group.Optical density represented the NK-1R protein content
in ASMCs.
ASMC culture
Twenty-four hours after the final challenge, the rats
were sacrificed, and primary ASMCs were cultured
according to a previously described method [9]. Tra-
cheas were dissected, excised, and washed aseptically.
The internal and external membranes of the trachea
were removed. The smooth muscles were separated lon-
gitudinally from the cartilage and digested in 0.1% tryp-
sin, 0.02% EDTA, and 0.2% type IV collagenase for 30
min in a shaking water bath at 37°C. The harvested cells
were collected and cultured in DMEM–F-12 medium (1:1
vol/vol; Thermo Scientific HyClone, Beijing, China) sup-
plemented with 10% FBS (Thermo Scientific HyClone,
Beijing, China). The medium was changed every 3 – 4
days. When the ASMCs reached confluency, exhibited an
elongated spindle shape, and grew with the typical hill-
and-valley appearance, the cells were passaged with a
0.25% trypsin – 0.02% EDTA solution. From then on, pas-
saging was performed every 10 – 14 days, and ASMCs of
the fourth passage were used for experiments. ASMCs
were identified using anti α-actin (1:200 diluted in PBS;Figure 3 The immunofluorescence of α-actin suggests that the
green-stained cells are ASMCs.
Table 3 NK-1R protein expression in ASMCs from the
different groups
Group Mean ± SE N
normal control group 0.3214±0.0181# 15
asthmatic group 0.3643±0.0221* 15
budesonide treatment group 0.3465±0.0156*# 15
*P < 0.05, compared with normal group; #P < 0.05, compared with asthmatic
group.
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conjugated goat-anti-rabbit (1:100, Invitrogen, Beijing,
China) and observed under a fluorescence microscope.
Immunocytochemistry and image analysis
The ASMCs from the different groups were cultured on
coverslips, and NK-1R protein expression was detected by
immuncytochemistry. After the cells reached confluency,
they were fixed in 4% polyphosphate formaldehyde, blocked
with peroxide and non-immune animal serum, and incu-
bated sequentially with primary antibody, biotin-labeled
secondary antibody, and streptomycin anti-biotin peroxi-
dase. Finally, the ASMCs were stained with DAB, counter-
stained with hematoxylin, dehydrated, cleared in xylene,
and fixed. Negative controls were generated by replacing
the primary antibody with PBS. To evaluate positive results,
five fields with condensed NK-1R protein expression were
selected under low magnification (×100), cell numbers were
counted under high magnification (×400), and the mean
density values of ASMCs with brown staining were calcu-
lated in the five selected fields via image analysis. Optical
density represented the NK-1R protein content in ASMCs.
Real-time RT-PCR analysis
To investigate NK-1R mRNA expression in ASMCs
from the various groups, real-time RT-PCR was per-
formed as a quantitative analysis. Total RNA was
extracted from ASMC cultures using RNAiso™ Plus
reagent (Takara, Dalian, China) and quantified using a
spectrophotometer. Following quantification, 2 μg of
RNA was reverse-transcribed into cDNA, and real-time
quantitative PCR assays were conducted using an ABIFigure 4 Immunocytochemical analysis of NK-1R protein expression i
B: Representative asthmatic group cell; C: Representative budesonide treatm
(Figure 4B) was significantly higher than that in the control group (P < 0.05
treatment group (P < 0.05; Figure 4C).PRISM 7500 real-time PCR System (Applied Biosys-
tems, Foster City, CA, USA) and the SYBR Prime-
Script™ RT-PCR kit reagent (Takara, Dalian, China).
The PCR conditions for NK-1R were 45 cycles of de-
naturation at 95°C for 5 s and annealing and extension
at 60°C for 30 s. Target mRNA levels were normalized
to those of GAPDH. The following oligonucleotide
primers were used: NK-1R forward 50-CGCCGATG
TTTCAGTCCATTC-30, reverse 50-GACGTATTCAGT
CCGTGTTGGTTG-30; GAPDH forward 50-GCACCGT
CAAGGCTGAGAAC-30, reverse 50-ATGGTGGTGAA
GACGCCAGT-30. Gene expression was determined by
the 2−ΔΔCT method.
Statistical analysis
All experiments were repeated in triplicate. All data were
expressed as the mean ± SE and analyzed using SPSS 17.
One-way analysis of variance with the SNK test was used
to test for significance, which was accepted at P < 0.05.
Results
Airway responsiveness to MCh
To test the airway responsiveness of asthmatic rats
in vivo, we measured respiratory parameter changes
induced by MCh. Airway responsiveness of rats in the
asthmatic group increased after induction by MCh when
compared to the control group. However, the airway
responsiveness of rats in the budesonide treatment
group decreased after induction by MCh when com-
pared with the asthmatic group (Figure 1).
Inflammatory cells in BAL fluid
The number of inflammatory cells in BAL fluid was
measured and compared between the three groups.
Remarkably, the total cell number and eosinophils in
BAL fluid recovered from OVA-sensitized/challenged
rats was significantly higher than that from PBS-treated
rats (P < 0.05). Conversely, total cells and eosinophils in
the budesonide treatment group were significantly
decreased when compared with the asthmatic groupn ASMCs from different groups. A: Representative control group cell;
ent group cell. The expression of NK-1R in the asthmatic group
; Figure 4A) but significantly lower than that in the budesonide
Table 4 NK-1RmRNA expression in different group ASMC
Group Mean ± SE N
normal control group 1.0347 ± 0.2503# 15
asthmatic group 1.1687 ± 0.1356* 15
budesonide treatment group 1.0820 ± 0.1146*# 15
*P < 0.05, compare with normal group;#P < 0.05, compare with asthmatic
group.
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control group (P > 0.05) (Table 1).
NK-1R protein expression in the lung
Immunohistochemistry was employed to investigate NK-1R
protein expression in airways. According to image analysis,
the expression of NK-1R protein in the asthmatic group
was significantly higher than that in the control group
(P < 0.05) but this increase was significantly abrogated by
budesonide treatment (P < 0.05; Figure 2 and Table 2).
However, NK-1R protein expression in the budesonide
treatment group remained significantly higher than that of
controls (P < 0.05).
NK-1R protein expression in ASMCs
To investigate NK-1R protein expression in ASMCs, we
first studied the purity of ASMCs of the fourth passage via
immunocytochemistry. Accordingly, the purity of ASMCs
was confirmed to exceed 95% by α-actin staining (Figure 3).
Image analysis revealed that, as in the aforementioned IHC
results, the protein expression of NK-1R in the asthmatic
group was significantly higher than that in the control
group (P < 0.05), but again this level was significantly
decreased by budesonide treatment (P < 0.05; Figure 4 and
Table 3). However, NK-1R protein expression in the bude-
sonide treatment group remained significantly higher than
that in the control group (P < 0.05).
NK-1R mRNA expression in ASMCs
Similar to the results observed in all protein expression
studies, real-time RT-PCR demonstrated that NK-1R
mRNA expression in the asthmatic group was significantly
greater than that of the control group (P < 0.05) but was
significantly lowered by budesonide treatment (P < 0.05;
Table 4). Yet, NK-1R mRNA expression in the budesonide
treatment group was still significantly greater than that of
the controls (P < 0.05).
Discussion
In this study, we utilized immunohistochemistry, immuno-
cytochemistry, image analysis, and real-time RT-PCR to
analyze NK-1R expression in the airways of asthmatic
rats. Immunohistochemistry detected that NK-1R mRNA
localizes near the tracheal epithelium superior layer cell
surface, mucosa, blood vessel epithelial cells, inflammatory
cell surface, smooth muscle cells, and gland cell surface.Furthermore, immunocytochemistry revealed NK-1R ex-
pression in the cytoplasm of ASMCs, important cells in the
asthmatic airway. Substance P binds preferentially to the
NK-1R and induces bronchoconstriction, increases mucus
secretion, and facilitates cholinergic neurotransmission,
vasodilatation, and plasma leakage [10]. The NK-1R is a
member of the tachykinin G-protein-coupled receptor
super family, known for influencing a broad array of
biological actions, including contraction, secretion,
immune responses, and neurotransmission [11].
Glucocorticoids (GCs) are commonly used therapeutic
drugs in the treatment of asthma, and they are generally
believed to act through an anti-inflammatory effect that
involves decreasing inflammatory factors by inhibiting cyto-
kine production and release. Accordingly, budesonide is an
inhaled GC that can inhibit inflammation of the asthmatic
airway, but the effect of this drug on neuropeptide-induced
inflammation in asthma is unknown.
Therefore, in our study, we compared NK-1R expres-
sion in the lung and ASMCs obtained from asthmatic
rats to those obtained from asthmatic rats treated with
budesonide. We found that NK-1R was downregulated
in ASMCs, which suggests that budesonide inhibited air-
way inflammation, at least in part, by downregulating
NK-1R expression in ASMCs.
It has been shown that GCs act through both genomic
and non-genomic mechanisms. The genomic effects of
GCs are generally mediated by cytosolic receptors that alter
the expression of specific genes [12]. However, in recent
decades, it has been demonstrated that GCs also act
through a membrane-initiated, non-genomic mechanism
[13-15] that has a rapid onset time, typically within minutes
or even seconds after stimulation, in contrast to the gen-
omic action that has an onset time of hours [14]. Further-
more, the genomic mechanism may be mediated through
classical GC receptors but may also have a transcription/
translation-independent component; these effects might be
mediated through some membrane-bound GC receptor
that has yet to be identified [13,14], as the action of GCs
involves the activation of multiple intracellular signal trans-
duction pathways [16]. Regardless, the rapid non-genomic
action of GCs has been extensively reported in the CNS
[14], and this action is biologically relevant, as Zhou et al
previously demonstrated the rapid non-genomic effects of
GCs on allergic asthmatic reactions in the guinea pig [17].
Though the mechanism is yet unknown, in the present
study, we show that GCs may inhibit airway inflammation
through reducing NK receptor expression. However, how
and to what extent GCs affect the function of neuropep-
tides remains to be investigated.
Conclusions
NK-1R is involved in the pathogenesis of asthma and
that budesonide may downregulate the expression of
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which may alleviate neurogenic airway inflammation.
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